Centessa Pharmaceuticals (NASDAQ:CNTA) Releases Earnings Results, Beats Estimates By $0.05 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) issued its quarterly earnings results on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05, Zacks reports.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $17.50 on Friday. The firm has a market capitalization of $1.98 billion, a P/E ratio of -11.44 and a beta of 1.47. The company has a quick ratio of 13.29, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock’s 50-day simple moving average is $15.87 and its two-hundred day simple moving average is $12.07. Centessa Pharmaceuticals has a twelve month low of $5.58 and a twelve month high of $18.74.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Jefferies Financial Group lifted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, BMO Capital Markets lifted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.17.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 4,169 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. The trade was a 0.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 12,198 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now directly owns 241,171 shares in the company, valued at approximately $2,935,051.07. This represents a 4.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 325,031 shares of company stock valued at $5,213,043. 11.59% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.